<DOC>
	<DOC>NCT00517894</DOC>
	<brief_summary>To investigate if a dose-dense chemotherapy with weekly chemotherapy compared to standard treatment every 3 weeks results in better survival in aggressive non-Hodgkin's lymphoma.</brief_summary>
	<brief_title>Dose-Dense Therapy in Aggressive Lymphoma</brief_title>
	<detailed_description>Patients are randomized to receive dose-dense CEOP/IMVP-Dexa chemotherapy or standard 3-weekly CHOP.</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Aggression</mesh_term>
	<criteria>18 and 70 years of age Centrally reviewed, histologically proven diffuse large Bcell, anaplastic largecell, or peripheral Tcell unspecified Measurable disease All stages Lymphoblastic or Burkitt histology CNSdisease HIVpositive pregnant or lactating women Pretreatment Other malignancy Concomitant diseases that forbid chemotherapy</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>August 2007</verification_date>
	<keyword>lymphoma</keyword>
	<keyword>aggressive</keyword>
	<keyword>chemotherapy</keyword>
	<keyword>dose-dense</keyword>
</DOC>